Genmab A (GMAB) Receivables (2023 - 2025)

Genmab A's Receivables history spans 3 years, with the latest figure at $1.2 billion for Q4 2025.

  • For Q4 2025, Receivables rose 22.17% year-over-year to $1.2 billion; the TTM value through Dec 2025 reached $1.2 billion, up 22.17%, while the annual FY2025 figure was $1.2 billion, 22.17% up from the prior year.
  • Receivables reached $1.2 billion in Q4 2025 per GMAB's latest filing, up from $979.0 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $1.2 billion in Q4 2025 to a low of $786.0 million in Q4 2023.
  • Average Receivables over 3 years is $987.0 million, with a median of $979.0 million recorded in 2024.
  • Peak YoY movement for Receivables: grew 24.55% in 2024, then increased 22.17% in 2025.
  • A 3-year view of Receivables shows it stood at $786.0 million in 2023, then increased by 24.55% to $979.0 million in 2024, then rose by 22.17% to $1.2 billion in 2025.
  • Per Business Quant, the three most recent readings for GMAB's Receivables are $1.2 billion (Q4 2025), $979.0 million (Q4 2024), and $786.0 million (Q4 2023).